Lyra therapeutics fully enrolls pivotal phase 3 enlighten i trial of lyr-210 for the treatment of chronic rhinosinusitis

Watertown, mass., aug. 29, 2023 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (crs), today announced that the pivotal phase 3 enlighten i clinical trial of lyr-210 in adult patients with crs who have not had prior ethmoid sinus surgery, is fully enrolled.
LYRA Ratings Summary
LYRA Quant Ranking